Diabetic Macular Edema Market Report and Forecast 2025-2034

The diabetic macular edema market size was valued at USD 6.70 Billion in 2024, driven by the increasing incidence of diabetes cases within the 8 major markets. The market size is anticipated to grow at a CAGR of 5.10% during the forecast period of 2025-2034 to achieve a value of USD 11.02 Billion by 2034.

Diabetic Macular Edema Market Overview

Diabetic retinopathy occurs in people with diabetes where the tiny blood vessels located at the back inner wall of the eye, known as the retina, get damaged or blocked by too much blood sugar. This can result in the formation of microaneurysms, which are tiny bulges in the blood vessels that leak fluid into the retina. The swollen fluid can cause vision problems or blindness in a part of the retina known as the macula, which is referred to as diabetic macular edema.

The market is driven by the rising prevalence of diabetes and diabetic macular edema. The prevalence rate of diabetic macular edema (DME) in type 2 diabetes patients is recorded to be higher than in type 1 diabetes patients. It is estimated that neovascular age-related macular degeneration (AMD) affects more than 200 million people worldwide. The increase in the number of research and development activities providing beneficial opportunities for treatment are driving the diabetic macular edema market growth. The rising approvals and launches of new drugs, along with rising investment in the development of advanced technologies is also expected to contribute to the market growth during the forecast period.

Technological Advancements to Develop Effective Solutions

The market growth is expected to be driven by several factors such as increased advancements in diagnostics technology and therapeutics for diabetic macular edema. For instance, in July 2023 researchers at the University of Waterloo’s School of Pharmacy developed a novel synthetic protein to treat macular degeneration and other incurable eye diseases that lead to blindness in millions of people. It is the first drug of its kind and is currently in human trials. Continuous efforts like these, focused at developing a cure for untreatable conditions are likely to increase the diabetic macular edema market share in the forecast period.

FDA Approvals to Aid the Market Growth

The market growth is propelled by rising FDA approvals to potent and cost-effective solutions to the patients. For instance, in August 2023, the United States FDA approved Regeneron’s EYLEA HD (aflibercept) Injection 8 mg for treating diabetic macular edema and other eye conditions. The approval was based on the results of 48-week PULSAR and PHOTON trials, wherein the potential candidate helped in significant vision gains in patients. This FDA approval will contribute to the widespread distribution and consumption of the pharmaceutical resulting in increased diabetic macular edema market value in the forecast period.

Diabetic Macular Edema Market Segmentations

Diabetic Macular Edema Market Report and Forecast 2025-2034 offers a detailed analysis of the market based on the following segments:

Market Breakup by Disease Type

• Focal Diabetic Macular Edema (DME)
• Diffuse Diabetic Macular Edema (DME)

Market Breakup by Treatment Type

• Oral Iron Therapy
• Parenteral Iron Therapy
• Red Blood Cell Transfusion

Market Breakup by Diagnosis

• Hospitals Fluorescein Angiography
• Fundus Imaging
• Optical Coherence Tomography (OCT)
• Others

Market Breakup by Route of Administration

• Intravitreal Injections
• Intravitreal Implants

Market Breakup by Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Market Breakup by End User

• Hospitals
• Clinics
• Home Healthcare
• Others

Market Breakup by Region

• United States
• EU-4 and the United Kingdom
• Germany
• France
• Italy
• Spain
• United Kingdom
• Japan
• India

Diabetic Macular Edema Market Regional Analysis

Geographically, the United States is expected to lead throughout the forecast period, owing to the presence of a robust healthcare system and major market players. The continuous research activities in the region also contribute to the market growth. There has been significant emphasis on leveraging gene therapy to allow access to improved solutions. In November 2023, scientists deployed gene therapy ABBV-RGX-314 to allow controlled release of dexamethasone in patients with diabetic macular edema and retinal vein occlusion. Developed by collaborative efforts of RegenXBio and AbbVie, ABBV-RGX-314 is a monoclonal antibody fragment, administered through an injection. When tested in a cohort of 100 patients with DME, it reduced vision threatening events by 89% and prevented disease progression as well. Hence, it can be used as a potential treatment in the future.

Europe, with its robust healthcare infrastructure and significant portion of geriatric population has high diabetic macular edema market demand. Consequently, the existence of prominent academic and research institutions aids market size, with continuous developments and activities to develop effective solutions for the patients in the region.

Diabetic Macular Edema Market: Competitor Landscape

In May 2023, Oculis, a global pharmaceutical company prioritising eye care, revealed that their latest topical eye drop OCS-01, displayed positive results from stage 1 of phase 3 DIAMOND trial . The treatment provides an edge over current treatment alternatives of the disease, which mostly involve ocular implants or injections. It utilises Oculis' Optireach technology to deliver the effective medication to the retina. The rising prevalence for minimally invasive treatment alternatives has led to the development of relevant initiatives by industry leaders.

The key features of the diabetic macular edema market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• LEO Pharma
• Amneal Pharmaceuticals
• AstraZeneca
• Johnson & Johnson Private Limited
• Bausch Health Companies Inc
• Eli Lilly and Company
• AbbVie Inc
• Abbott
• F. Hoffmann-La Roche Ltd
• Mylan N.V

Please note that this only represents a partial list of companies, and the complete list has been provided in the report.

This product will be delivered within 3-5 business days.